These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 24274865)

  • 21. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gut microbiota interactions with obesity, insulin resistance and type 2 diabetes: did gut microbiote co-evolve with insulin resistance?
    Esteve E; Ricart W; Fernández-Real JM
    Curr Opin Clin Nutr Metab Care; 2011 Sep; 14(5):483-90. PubMed ID: 21681087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.
    Chen J; Thomsen M; Vitetta L
    J Cell Biochem; 2019 Mar; 120(3):2713-2720. PubMed ID: 30443932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.
    Kirpich IA; Marsano LS; McClain CJ
    Clin Biochem; 2015 Sep; 48(13-14):923-30. PubMed ID: 26151226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet.
    Machado MV; Cortez-Pinto H
    Int J Mol Sci; 2016 Apr; 17(4):481. PubMed ID: 27043550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of dietary fat on gut microbiota and low-grade systemic inflammation: mechanisms and clinical implications on obesity.
    Cândido FG; Valente FX; Grześkowiak ŁM; Moreira APB; Rocha DMUP; Alfenas RCG
    Int J Food Sci Nutr; 2018 Mar; 69(2):125-143. PubMed ID: 28675945
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Gordian Knot of dysbiosis, obesity and NAFLD.
    Mehal WZ
    Nat Rev Gastroenterol Hepatol; 2013 Nov; 10(11):637-44. PubMed ID: 23958600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intestinal microbiota and obesity.
    Blaut M; Klaus S
    Handb Exp Pharmacol; 2012; (209):251-73. PubMed ID: 22249818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Probiotics, prebiotics, energy balance, and obesity: mechanistic insights and therapeutic implications.
    Molinaro F; Paschetta E; Cassader M; Gambino R; Musso G
    Gastroenterol Clin North Am; 2012 Dec; 41(4):843-54. PubMed ID: 23101690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk.
    Manco M; Putignani L; Bottazzo GF
    Endocr Rev; 2010 Dec; 31(6):817-44. PubMed ID: 20592272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Do nutrient-gut-microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes?
    Diamant M; Blaak EE; de Vos WM
    Obes Rev; 2011 Apr; 12(4):272-81. PubMed ID: 20804522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gut microbiota and non-alcoholic fatty liver disease.
    Gkolfakis P; Dimitriadis G; Triantafyllou K
    Hepatobiliary Pancreat Dis Int; 2015 Dec; 14(6):572-81. PubMed ID: 26663004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microbiota and nonalcoholic steatohepatitis.
    Imajo K; Yoneda M; Ogawa Y; Wada K; Nakajima A
    Semin Immunopathol; 2014 Jan; 36(1):115-32. PubMed ID: 24337650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intestinal microbiota in patients with nonalcoholic fatty liver disease.
    Mouzaki M; Comelli EM; Arendt BM; Bonengel J; Fung SK; Fischer SE; McGilvray ID; Allard JP
    Hepatology; 2013 Jul; 58(1):120-7. PubMed ID: 23401313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders.
    Musso G; Gambino R; Cassader M
    Curr Opin Lipidol; 2010 Feb; 21(1):76-83. PubMed ID: 19915460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review: The role of insulin resistance in nonalcoholic fatty liver disease.
    Utzschneider KM; Kahn SE
    J Clin Endocrinol Metab; 2006 Dec; 91(12):4753-61. PubMed ID: 16968800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.
    Han R; Ma J; Li H
    Front Med; 2018 Dec; 12(6):645-657. PubMed ID: 30178233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reshaping the gut microbiota at an early age: functional impact on obesity risk?
    Luoto R; Collado MC; Salminen S; Isolauri E
    Ann Nutr Metab; 2013; 63 Suppl 2():17-26. PubMed ID: 24217033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Probiotics in Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, and Cirrhosis.
    Qamar AA
    J Clin Gastroenterol; 2015; 49 Suppl 1():S28-32. PubMed ID: 26447961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Probiotics in non-alcoholic fatty liver disease: which and when.
    Abenavoli L; Scarpellini E; Rouabhia S; Balsano C; Luzza F
    Ann Hepatol; 2013; 12(3):357-63. PubMed ID: 23619251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.